RXDX
Income statement / Annual
Last year (2023), Prometheus Biosciences, Inc.'s total revenue was $6.81 M,
an increase of 117.61% from the previous year.
In 2023, Prometheus Biosciences, Inc.'s net income was -$141.75 M.
See Prometheus Biosciences, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$6.81 M
|
$3.13 M
|
$1.23 M
|
$1.12 M
|
$0.00
|
$0.00
|
$150,000.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$6.81 M |
$3.13 M |
$1.23 M |
$1.12 M |
$0.00 |
$0.00 |
$150,000.00 |
| Gross Profit Ratio |
1 |
1 |
1 |
1 |
0 |
0 |
1 |
| Research and Development
Expenses |
$112.85 M
|
$62.43 M
|
$19.15 M
|
$10.96 M
|
$76.93 M
|
$73.51 M
|
$30.51 M
|
| General & Administrative
Expenses |
$39.74 M
|
$28.51 M
|
$11.09 M
|
$6.13 M
|
$23.76 M
|
$17.07 M
|
$9.49 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$39.74 M
|
$28.51 M
|
$11.09 M
|
$6.13 M
|
$23.76 M
|
$17.07 M
|
$9.49 M
|
| Other Expenses |
$4.03 M |
-$2.39 M |
-$15,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$152.59 M |
$90.93 M |
$30.24 M |
$17.09 M |
$100.68 M |
$90.58 M |
$40.00 M |
| Cost And Expenses |
$152.59 M |
$90.93 M |
$30.24 M |
$17.09 M |
$100.68 M |
$90.58 M |
$40.00 M |
| Interest Income |
$4.03 M |
$108,000.00 |
$13,000.00 |
$9,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$861,000.00 |
$2.13 M |
$770,000.00 |
$3.21 M |
$2.59 M |
$0.00 |
| Depreciation &
Amortization |
$629,000.00
|
$258,000.00
|
$107,000.00
|
$44,000.00
|
$3.48 M
|
$2.04 M
|
$527,675.00
|
| EBITDA |
-$145.78 M
|
-$87.80 M
|
-$28.90 M
|
-$15.92 M
|
-$96.95 M
|
-$87.83 M
|
-$39.45 M
|
| EBITDA Ratio |
-21.41 |
-28.06 |
-23.52 |
-14.24 |
0 |
0 |
-263 |
| Operating Income Ratio
|
-21.41
|
-28.06
|
-23.6
|
-14.28
|
0
|
0
|
-265.66
|
| Total Other
Income/Expenses Net |
$4.03 M
|
-$2.39 M
|
-$2.13 M
|
-$761,000.00
|
-$2.96 M
|
-$1.88 M
|
-$128,421.00
|
| Income Before Tax |
-$141.75 M |
-$90.20 M |
-$31.14 M |
-$16.73 M |
-$103.64 M |
-$92.46 M |
-$39.98 M |
| Income Before Tax Ratio
|
-20.82
|
-28.83
|
-25.34
|
-14.96
|
0
|
0
|
-266.52
|
| Income Tax Expense |
-$629,000.00 |
-$258,000.00 |
$8.11 M |
$13.76 M |
$259,000.00 |
$715,000.00 |
$12,330.00 |
| Net Income |
-$141.75 M |
-$89.94 M |
-$39.25 M |
-$30.49 M |
-$103.64 M |
-$92.46 M |
-$39.99 M |
| Net Income Ratio |
-20.82 |
-28.74 |
-31.94 |
-27.27 |
0 |
0 |
-266.6 |
| EPS |
-3.49 |
-2.87 |
-1.13 |
-1.13 |
-2.69 |
-3.44 |
-2.18 |
| EPS Diluted |
-3.49 |
-2.87 |
-1.13 |
-1.13 |
-2.69 |
-3.44 |
-2.18 |
| Weighted Average Shares
Out |
$40.62 M
|
$31.33 M
|
$34.61 M
|
$26.98 M
|
$38.48 M
|
$26.85 M
|
$18.33 M
|
| Weighted Average Shares
Out Diluted |
$40.62 M
|
$31.33 M
|
$34.61 M
|
$26.98 M
|
$38.48 M
|
$26.85 M
|
$18.33 M
|
| Link |
|
|
|
|
|
|
|
